MDM2 and acute myeloid leukemia: Regarding the growing field of TP53-activating compounds [46] and targeted therapy against TP53 pathway genes [47] (e. g., MDM2), a better characterization of mutational and non-mutational TP53 alterations will become useful in the initial workup of each AML patient [48].